A Phase III Study of TRC105 plus Pazopanib versus Pazopanib Alone to Treat Advanced Angiosarcoma

Full Title

105SAR301: A Randomized Phase III Trial of TRC105 and Pazopanib versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS)


Pazopanib is a drug used to treat soft tissue sarcomas, including angiosarcoma. It works by inhibiting the growth of blood vessels that tumors need to grow and spread. But sometimes the sarcoma continues to grow or comes back. In this study, researchers want to see if combining pazopanib with the investigational drug TRC105 (carotuximab) is more effective against advanced angiosarcoma than pazopanib alone.

TRC105 is an antibody that also inhibits blood vessel growth, though by targeting a different protein than pazopanib. Earlier studies have shown that combining TRC105 with pazopanib may be more effective against soft tissue sarcoma than pazopanib alone. In this study, patients will be randomly assigned to receive the two drugs together, or just pazopanib. TRC105 is given intravenously (by vein), while pazopanib is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic angiosarcoma.
  • Patients may not have received more than two prior regimens of chemotherapy.
  • Patients must recover from the serious side effects of any prior therapies.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older. Patients ages 12-17 may participate if they weigh 40 kg (88 lbs) or more.

For more information about this study and to inquire about eligibility, please contact Dr. William Tap at 646-888-4163.